首页> 外文期刊>European journal of pharmaceutical sciences >Solid self-nanoemulsifying drug delivery system (S-SNEDDS) of darunavir for improved dissolution and oral bioavailability: In vitro and in vivo evaluation
【24h】

Solid self-nanoemulsifying drug delivery system (S-SNEDDS) of darunavir for improved dissolution and oral bioavailability: In vitro and in vivo evaluation

机译:darunavir的固体自纳米乳化药物递送系统(S-SNEDDS),用于改善溶出度和口服生物利用度:体外和体内评估

获取原文
获取原文并翻译 | 示例
           

摘要

The current study was aimed to investigate the potential of solid self-nanoemulsifying drug delivery system (S-SNEDDS) composed of Capmul MCM C8 (oil), Tween 80 (surfactant) and Transcutol P (co-surfactant) in improving the dissolution and oral bioavailability of darunavir. Liquid self-nanoemulsifying drug delivery systems (L-SNEDDS) were developed by using rational blends of components with good solubilizing ability for darunavir which were selected based on solubility studies, further ternary phase diagram was constructed to determine the self-emulsifying region. The prepared L-SNEDDS formulations were evaluated to determine the effect of composition on physicochemical parameters like rate of emulsification, clarity, phase separation, thermodynamic stability, cloud point temperature, globule size and zeta potential. In vitro drug release studies showed initial rapid release of about 13.3 +/- 1.4% within 30 min from L-SNEDDS followed by slow continuous release of entrapped drug and reached a maximum of 62.6 +/- 3.5% release at the end of 24 h. The globule size analysis revealed the formation of nanoemulsion (144 +/- 2.3 nm) from the optimized L-SNEDDS formulation and was physically adsorbed onto neusilin US2. In vitro dissolution studies indicated faster dissolution of darunavir from the developed S-SNEDDS with 3 times greater mean dissolution rate (MDR) compared to pure darunavir. Solid state studies concluded the presence of drug in non-crystalline amorphous state without any significant interaction of drug with the components of S-SNEDDS. Furthermore, in vivo pharmacokinetic studies in Wistar rats resulted in enhanced values of peak drug concentration (C-max) for L-SNEDDS (2.98 +/- 0.19 mu g/mL) and S-SNEDDS (3.7 +/- 0.28 mu g/mL) compared to pure darunavir (1.57 +/- 0.17 mu g/mL). (C) 2015 Elsevier B.V. All rights reserved.
机译:本研究旨在研究由Capmul MCM C8(油),Tween 80(表面活性剂)和Transcutol P(辅助表面活性剂)组成的固体自纳米乳化药物递送系统(S-SNEDDS)在改善溶出度和口服性方面的潜力达那那韦的生物利用度。液体自纳米乳化药物输送系统(L-SNEDDS)是通过对溶解度研究基础上选择的对地瑞纳韦具有良好溶解能力的组分的合理共混物而开发的,并进一步构建了三元相图来确定自乳化区域。评价所制备的L-SNEDDS制剂,以确定组合物对理化参数如乳化率,澄清度,相分离,热力学稳定性,浊点温度,小球尺寸和ζ电势的影响。体外药物释放研究表明,L-SNEDDS在30分钟内最初快速释放约13.3 +/- 1.4%,然后缓慢连续释放所包埋的药物,并在24小时结束时最大释放62.6 +/- 3.5% 。球大小分析显示,由优化的L-SNEDDS配方形成了纳米乳状液(144 +/- 2.3 nm),并被物理吸附到Neusilin US2上。体外溶出度研究表明,与纯地那那韦相比,地瑞那韦从发达的S-SNEDDS中溶出得更快,平均溶出率(MDR)高3倍。固态研究得出的结论是,药物存在于非晶态非晶态,而药物与S-SNEDDS的成分之间没有任何明显的相互作用。此外,在Wistar大鼠中进行体内药代动力学研究,发现L-SNEDDS(2.98 +/- 0.19μg / mL)和S-SNEDDS(3.7 +/- 0.28μg/ mL)的峰值药物浓度(C-max)值提高了毫升)与纯darunavir(1.57 +/- 0.17微克/毫升)相比。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号